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Generation of Safe and Therapeutically
Effective Human Induced Pluripotent
Stem Cell-Derived Hepatocyte-Like
Cells for Regenerative Medicine
Kazuo Takayama,1–3* Naoki Akita,1,3* Natsumi Mimura,3 Rina Akahira,4 Yukimasa Taniguchi,5 Makoto Ikeda,6
Fuminori Sakurai,1,7 Osamu Ohara,6 Tomohiro Morio,8 Kiyotoshi Sekiguchi,5 and Hiroyuki Mizuguchi1,3,9
Hepatocyte-like cells (HLCs) differentiated from human induced pluripotent stem (iPS) cells are expected to be applied for
regenerative medicine. In this study, we attempted to generate safe and therapeutically effective human iPS-HLCs for hepato-
cyte transplantation. First, human iPS-HLCs were generated from a human leukocyte antigen-homozygous donor on the
assumption that the allogenic transplantation might be carried out. Highly efficient hepatocyte differentiation was performed
under a feeder-free condition using human recombinant laminin 111, laminin 511, and type IV collagen. The percentage of
asialoglycoprotein receptor 1-positive cells was greater than 80%, while the percentage of residual undifferentiated cells was
approximately 0.003%. In addition, no teratoma formation was observed even at 16 weeks after human iPS-HLC transplanta-
tion. Furthermore, harmful genetic somatic single-nucleotide substitutions were not observed during the hepatocyte differen-
tiation process. We also developed a cryopreservation protocol for hepatoblast-like cells without negatively affecting their
hepatocyte differentiation potential by programming the freezing temperature. To evaluate the therapeutic potential of human
iPS-HLCs, these cells (13 106 cells/mouse) were intrasplenically transplanted into acute liver injury mice treated with 3mL/
kg CCl4 only once and chronic liver injury mice treated with 0.6mL/kg CCl4 twice weekly for 8 weeks. By human iPS-HLC
transplantation, the survival rate of the acute liver injury mice was significantly increased and the liver fibrosis level of chronic
liver injury mice was significantly decreased. Conclusion: We were able to generate safe and therapeutically effective human
iPS-HLCs for hepatocyte transplantation. (Hepatology Communications 2017;1:1058-1069)
Introduction
O
rthotopic liver transplantation and hepato-
cyte transplantation are effective treatments
against chronic liver failure, acute liver fail-
ure, and hereditary liver diseases.(1,2) However, the
shortage of donor livers and hepatocytes is a serious
problem. Therefore, hepatocyte-like cells (HLCs) dif-
ferentiated from human induced pluripotent stem
(iPS) cells, which have the potential to self-replicate
and differentiate into almost all types of cells, would be
an attractive cell source.(3) Several groups, including us,
have developed hepatocyte differentiation technologies
from human iPS cells and have demonstrated the ther-
apeutic potential of human iPS-HLCs against liver
failure by using mice models of liver failure.(4-7) How-
ever, the clinical application of human iPS-HLCs has
not been realized because the safety of human iPS-
Abbreviations: AFP, alpha-fetoprotein; ALB, albumin; CiRA, Center for iPS Cell Research and Application; CYP3A4, cytochrome P450, subfamily
3, polypeptide A4; ES, embryonic stem; HBC, hepatoblast-like cell; HGF, hepatocyte growth factor; HLA, human leukocyte antigen; HLA-homo,
human leukocyte antigen homozygous; HLC, hepatocyte-like cell; HLC-CD, hepatocyte-like cells generated by current hepatocyte differentiation method;
HLC-CNV, hepatocyte-like cells generated by conventional hepatocyte differentiation method; iPS, induced pluripotent stem; LN111-E8, LN511-E8,
recombinant laminin-111 or 511 E8 fragment; NOG, NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic; PHH, primary human hepatocyte.
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HLC transplantation has not been sufficiently verified.
Therefore, a method to generate human iPS-HLCs
that are not only therapeutically effective but also safe
is urgently needed.
The major concerns of the clinical application of
iPS cell derivatives (including hepatocytes) are tera-
toma formation, oncogenesis, and immune rejec-
tion.(8) To address these concerns, measuring the rate
of residual undifferentiated cells and evaluating the
risk of teratoma formation by transplanting iPS cell
derivatives into immunodeficient mice are necessary
steps.(9) It is also necessary to determine whether
harmful genetic mutations arise during the reprog-
ramming and directed differentiation. Although
autologous transplantation of iPS cell derivatives is
preferable to avoid transplant rejection, the custom-
ized preparation of iPS cell derivatives for individual
patients is time consuming and expensive. For this
reason, allogenic transplantation using human iPS
cells from a separate donor is eagerly anticipated. In
human leukocyte antigen (HLA)-mismatched trans-
plantation, graft versus host reaction and transplant
rejection will occur with high probability. Therefore,
with the goal of preventing transplant rejection,
human iPS cells were established from an HLA-
homozygous donor (a donor who received the same
HLA from both parents; this describes 2%-4% of the
Japanese population) for allogenic transplantation at
the Center for iPS Cell Research and Application
(CiRA), Kyoto University. It is necessary to generate
human iPS-HLCs from an HLA-homozygous donor
to perform transplantation in a large number of
patients with liver failure. In addition, a hepatocyte
differentiation protocol with minimal or no use of
serum, Matrigel, or feeder cells is also needed to avoid
unexpected adverse events.
In this study, HLA homozygous human iPS cells
(HLA-homo iPS cells), which were provided from the
CiRA, were differentiated into HLCs without using
feeder cells, Matrigel, or serum. The risk of teratoma
formation and oncogenesis was evaluated. To evaluate
the therapeutic effects of human iPS-HLCs, we trans-
planted these cells into acute and chronic liver-failure
model mice. Our aim was to generate safe and
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therapeutically effective human iPS-HLCs that have
the potential to be applied in clinical applications.
Materials and Methods
STUDY APPROVAL
This study was approved by the ethics committees
of Osaka University and the National Institutes of Bio-
medical Innovation, Health, and Nutrition. All experi-
ments were performed in accordance with relevant
guidelines and regulations and with the approval of
Osaka University and the National Institutes of Bio-




mice (Central Institute for Experimental Animals)(10)
were intraperitoneally infused with 3mL/kg CCl4
(Wako) 1 day before transplantation. To obtain single-
cell suspension of human iPS-HLCs for the transplan-
tation, human iPS-HLCs were treated with a mixture
of 1mg/mL dispase (Roche) and 1mg/mL collagenase
(SERVA Electrophoresis GmbH) for 30 minutes.
Recipient mice were anesthetized with isoflurane
(Pfizer) and injected with 13 106 viable human iPS-
HLCs through a small left-flank incision into the infe-
rior splenic pole. Hepatocyte Culture Medium (Lonza)
was used as the injection vehicle. After hepatocyte
transplantation, the spleen was tied with sutures tight
enough to achieve hemostasis.
Results
CHARACTERIZATION
OF HLA-Homo iPS CELLS
We used HLA-homo human iPS cells that had
been established at CiRA, Kyoto University. To gener-
ate human iPS cells, peripheral blood mononuclear
cells were collected from a healthy donor and were
transfected with four plasmids (pCE-hSK, pCE-hUL,
pCE-hOCT4, and pCE-mp53DD).(11) The human
iPS cell line Ff-l01s01 was generated from an HLA-
homozygous donor. The human iPS cell line 1383D6
was established from a non-HLA-homozygous donor,
using the same materials and methods as for Ff-
l01s01. To assess the quality of human iPS cells, nine
tests were performed (Supporting Fig. S1A) at CiRA.
Donor information is summarized in Supporting Fig.
S1B, and the morphology of these iPS cells is shown
in Supporting Fig. S2A. We examined whether there
was a difference in cellular morphology between the
feeder-free iPS culture method and the on-feeder iPS
culture method (Supporting Fig. S2B). In the case of
the former, human iPS cells were cultured with AK03
medium, which consists solely of refined substances
completely free of animal-derived components, on a
human recombinant laminin (LN)511-E8 fragment
(LN511E8). For the on-feeder iPS culture method,
human iPS cells were cultured with ReproStem
medium, which contains animal-derived components,
on mouse embryonic fibroblasts. The human iPS cells
were cultured for five passages under each condition.
There were no significant differences in the gene
expression levels of pluripotent markers (octamer-bind-
ing transcription factor 3/4 [OCT3/4] and homeobox
protein NANOG [NANOG] or definitive endoderm
markers (forkhead box A2 [FOXA2] and sex determining




In our previous reports, Matrigel was used for hepa-
toblast differentiation. However, human iPS cells,
which were cultured on LN511-E8, hardly adhered to
Matrigel. Interestingly, we found that the gene expres-
sion levels of collagen receptors (integrins a1, a2, a4,
a10, and a11) were lower in the culture on LN511-E8
than in the culture on mouse embryonic fibroblasts
(Supporting Fig. S3). This suggests that human iPS
cells, which were cultured on LN511-E8, are attach-
able to laminin rather than collagen. Therefore, we
decided to use laminins for hepatoblast differentiation.
Human iPS cells (1383D6) cultured on LN511-E8
were dissociated and plated onto a mixture of LN511-
E8 and LN111-E8 because human pluripotent stem
cells can be maintained on LN511-E8(12) and we had
reported that hepatoblast-like cells (HBCs) could be
maintained on LN111.(12-14) Human iPS cells were
precultured on laminins and differentiated into HBCs
by definitive endoderm cells (Supporting Fig. S4A).
The cell viability (Supporting Fig. S4B) and gene
expression levels of pluripotent markers (OCT3/4 and
NANOG) (Supporting Fig. S4C) in human iPS cells
cultured on LN511-E8 were similar to those of human
iPS cells cultured on a mixture of LN511-E8 and
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LN111-E8. After hepatoblast differentiation, the gene
expression levels of hepatoblast markers (alpha-fetopro-
tein [AFP] and hepatocyte nuclear factor 4 [HNF4a])
(Supporting Fig. S4D) and the percentage of AFP-
positive cells (Supporting Fig. S4E) in HBCs, which
were cultured on a mixture of LN511-E8 and LN111-
E8 at a ratio of 1:3, were the highest as compared with
other culture condition. These results suggest that the
maintenance of human iPS cells and hepatoblast dif-
ferentiation can be accomplished on a mixture of
LN511-E8 and LN111-E8 at a ratio of 1:3.
PURIFICATION OF HBCs AND
ELIMINATION OF RESIDUAL
UNDIFFERENTIATED CELLS
To purify human iPS cell-derived HBCs (human
iPS-HBCs), human iPS cell-derived cells were dissoci-
ated and plated onto various laminin isoforms. By
using LN111 or LN111-E8, the percentage of AFP-
positive cells reached almost 100% (Supporting Fig.
S5A). In addition, LN111-E8 could maintain the
AFP-positive cells at a lower concentration (0.5 lg/
cm2) compared to LN111 (4 lg/cm2) (Supporting Fig.
S5B). These results suggest that human iPS-HBCs
could be purified by using LN111-E8. To estimate the
percentage of residual undifferentiated cells in human
iPS-HBCs, the percentage of Tral-60-positive cells in
the nonpurified or purified iPS-HBCs was measured
(Supporting Fig. S5C) and was 12.2% in the nonpuri-
fied iPS-HBCs versus 2.7% in the purified iPS-HBCs
(Supporting Fig. S5D). However, because not all
Tra1-60-positive cells have proliferative activity as plu-
ripotent stem cells, a colony formation assay was per-
formed (Supporting Fig. S5E) to strictly estimate the
number of residual undifferentiated cells. The Tra1-
60-positive cells in nonpurified or purified iPS-HBCs
were sorted and cultured with AK03 medium on
LN511-E8 for 10 days. The percentage of residual
undifferentiated cells in purified iPS-HBCs was
approximately 0.003% versus approximately 0.385% in
nonpurified iPS-HBCs. The results indicated that the
percentage of residual undifferentiated cells was




To differentiate HLCs from human iPS-HBCs,
human iPS-HBCs were sequentially treated with
hepatocyte growth factor (HGF) and oncostatin M
(OsM). During the hepatocyte maturation process,
HLCs were overlaid with type I or IV collagen (Sup-
porting Fig. S6A). The gene expression levels of hepa-
tocyte markers (alpha-1 antitrypsin [AAT] and albumin
[ALB]) in human iPS-HLCs overlaid with thin layer
of type IV collagen were similar to those in primary
human hepatocytes (PHHs) (Supporting Fig. S6B). In
addition, the percentage of hepatocyte marker (ALB
and asialoglycoprotein receptor 1)-positive cells was
more than 80% (Supporting Fig. S6C). These results
suggest that functional human iPS-HLCs were effi-




Our current hepatocyte differentiation method is
schematically shown in Fig. 1A. After hepatocyte dif-
ferentiation, the morphology of the HLCs was similar
to that of the PHHs, which were polygonal with dis-
tinct round binuclei (Fig. 1B). Human iPS-HLCs
were stained for cytoplasmic glycogen using the peri-
odic acid–Schiff staining procedure, suggesting that
human iPS-HLCs could store glycogen (Fig. 1B). We
also confirmed that human iPS-HLCs were positive
for cytochrome P450 family 3 subfamily A member 4
(CYP3A4) and ALB by immunostaining (Fig. 1B).
Next, we compared our current hepatocyte differentia-
tion method with our previous hepatocyte differentia-
tion method using mouse embryonic fibroblasts,
serum, and Matrigel.(15) There was no significant dif-
ference in the gene expression levels of hepatocyte
markers (Fig. 1C), ALB (Fig. 1D, left), or urea (Fig.
1D, right) secretion capacities between human iPS-
HLCs generated by our current hepatocyte differentia-
tion method (HLC-CD) and human iPS-HLCs gen-
erated by our conventional hepatocyte differentiation
method (HLC-CNV). In addition to the ALB and
urea secretion capacities, there was no significant dif-
ference in the activities of CYP1A2 and CYP3A4
(Fig. 1E). To examine the induction potencies of
CYP1A2, CYP2B6, and CYP3A4, we treated HLC-
CNV and HLC-CD with omeprazole, phenobarbital,
and rifampicin, which are known to induce CYP1A2,
CYP2B6, and CYP3A4, respectively (Fig. 1F). The
induction potency of the CYPs in HLC-CD was simi-
lar to that of the CYPs in HLC-CNV. These results
suggest that our current hepatocyte differentiation
method could efficiently generate functional human
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FIG. 1. Evaluation of hepatocyte functionality of human iPS cell-derived HLCs. (A) The procedure for differentiation of human iPS
cells (1383D6) into HLCs is presented schematically. Details of the hepatic differentiation procedure are described in the Materials
and Methods. (B) A phase image of the HLCs is shown. Glycogen storage in the HLCs was confirmed by PAS staining. The expres-
sion of the hepatocyte markers (CYP3A4 and ALB) was examined by immunohistochemistry on day 32 of the differentiation. Nuclei
were counterstained with DAPI (blue). (C) The gene expression levels of hepatocyte markers (ALB, AAT, CYP3A4, CYP2C9, BSEP,
and NTCP) in undifferentiated human iPS cells, HLC-CNV (mouse embryonic fibroblasts, Matrigel, and serum were used(15)),
HLC-CD, and PHHs were examined by real-time RT-PCR. The gene expression levels in the PHHs were taken as 1.0. (D) The
amounts of ALB (left) and urea (right) secretion were examined in undifferentiated human iPS cells, HLC-CNV, HLC-CD, and
PHHs. (E) CYP1A2 (left) and 3A4 (right) activity levels were also examined. (F) To examine CYP1A2 (left), 2B6 (middle), and
3A4 (right) induction potency, the cells were treated with 50lM omeprazole for 24 hours, 500lM phenobarbital for 48 hours, or
20lM rifampicin for 48 hours; these agents are known to induce CYP1A2, 2B6, and 3A4, respectively. The gene expression levels of
the CYPs were measured by real-time RT-PCR. Controls were treated with DMSO (final concentration 0.1%). The gene expression
levels in the DMSO-treated PHHs were taken as 1.0. All data are represented as means6 SEM (n 5 3). Abbreviations: AAT, alpha-
1 antitrypsin; BMP4, bone morphogenetic protein 4; BSEP, bile salt export pump; DAPI, 4,6-diamidino-2-phenylindole; DMSO,
dimethyl sulfoxide; EGF, epidermal growth factor; FGF, fibroblast growth factor; NTCP, sodium/taurocholate co-transporting polypep-
tide; OsM, oncostatin M; PAS, periodic acid–Schiff; RT-PCR, reverse-transcription polymerase chain reaction.
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iPS-HLCs as effectively as our conventional hepatocyte
differentiation method. To confirm the robustness of
our hepatocyte differentiation method, four human iPS
cell lines (1231A3, Ff-l01s01, Ff-l01, and Ff-l14) were
differentiated into HLCs (Supporting Fig. S7). Similar
results were obtained by using other iPS cell lines.
CRYOPRESERVATION OF HBCs
We next attempted to develop a cryopreservation
protocol for HBCs. HBC cryopreservation would
allow us to store a stock of HBCs so that we could
avoid having to differentiate large amounts of cells at
the same time. To strictly control the temperature of
the freezing cells, we used the program Deep Freezer
(PDF300) and found that the cell recovery rate was
highest in the thermal management of “condition 3”
(Fig. 2A). In addition, the cell recovery rate was high-
est by using the cryopreservation medium
“Bambanker” (Fig. 2B). We also found that the per-
centage of AFP-positive cells largely depended on cell
seeding density (Fig. 2C). The percentage of AFP-
positive cells was almost 100% in the high-density
cell-culture condition (1.253 105 cells/cm2). The final
procedure for freezing human iPS-HBCs is shown in
Fig. 2D. The cell recovery rate after cryopreservation
was 78.7% (Fig. 2E). In addition, to examine the effect
of cryopreservation on hepatocyte differentiation
capacity, the nonfrozen iPS-HBCs and frozen iPS-
HBCs were differentiated into HLCs. The gene
expression levels of hepatocyte markers (ALB, AAT,
CYP3A4, and CYP2C9) in human iPS-HLCs differen-
tiated from the frozen iPS-HBCs were similar to those
in human iPS-HLCs differentiated from the nonfro-
zen iPS-HBCs (Fig. 2F). Moreover, similar results
were obtained by using an HLA-homo iPS cell line
(Ff-l01s01) (Supporting Fig. S8). These results suggest
that human iPS-HBCs could be cryopreserved without
negatively affecting their hepatocyte differentiation
potential.
SAFETY ASSESSMENT OF HLCs
To assess the safety of human iPS-HLCs, we first
performed a teratoma formation assay (Fig. 3A).
Immunodeficient mice were subcutaneously trans-
planted with undifferentiated human iPS cells
(13 105 cells/NOG mouse), human iPS cell-derived
purified HBCs (13 105 or 13 107 cells/NOG
mouse), and human iPS cell-derived HLCs (13 105
or 13 107 cells/NOG mouse). Teratoma formation
was observed at 4 weeks after transplantation in the
mice transplanted with undifferentiated human iPS
cells. However, no teratoma formation was observed
even at 16 weeks after transplantation in the mice
transplanted with human iPS cell-derived purified
HBCs and human iPS-HLCs. In addition, no tera-
toma formation was observed in the mice transplanted
with Tra1-60-positive cells in purified HBCs
(2.73 105, 2.73 106, or 2.73 107 cells/NOG mouse)
(Supporting Fig. S5F). Next, we examined whether a
cancer-related somatic mutation was introduced during
hepatoblast and/or hepatocyte differentiation by per-
forming targeted sequencing with a comprehensive
cancer panel (Fig. 3B). The genomic sequences of 596
cancer-related genes in human iPS-HBCs, purified
iPS-HBCs, and human iPS-HLCs were compared
with that of undifferentiated human iPS cells. To min-
imize the number of false-positive substitution calls,
three independent bioinformatics tools (LoFreq,
MuTech, and VarScan2) were collectively used because
the somatic variant call with either bioinformatics tool
has a considerably high false-positive rate.(16,17) Thus,
we considered that single substitutions detected by all
three bioinformatics tools would be likely candidates
for somatic variations newly generated during differen-
tiation; however, we did not observe any likely candi-
date for somatic variation in the 596 cancer-related
genes during the hepatoblast and hepatocyte differenti-
ation (Fig. 3B). To further characterize human iPS-
HBCs and iPS-HLCs, RNA sequencing analysis was
performed in undifferentiated human iPS cells, human
iPS-HBCs, purified iPS-HBCs, and iPS-HLCs (Fig.
3C,D). Messenger RNA expression profiles of plurip-
otent markers in human iPS-HBCs, purified iPS-
HBCs, and iPS-HLCs were largely different from
those of undifferentiated human iPS cells (Fig. 3C). In
addition, human iPS cells obtained liver-specific gene
expression patterns during the hepatocyte differentia-
tion process (Fig. 3D). Taken together, these results
show that human iPS-HBCs and iPS-HCLs have a
low risk of teratoma formation and oncogenesis.
TRANSPLANTATION OF
HLA-homo iPS CELL-DERIVED
HLCs RESCUED MICE FROM
ACUTE LIVER INJURIES
To evaluate the therapeutic potential of human iPS-
HLCs, these cells were transplanted into mice with
acute or chronic liver injury. As a mouse model of
acute liver injury, we used immunodeficient mice
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FIG. 2. Cryopreservation of human iPS cell-derived HBCs. (A) Human iPS cell (1383D6)-derived HBCs were cryopreserved under
three different conditions. We counted the number of viable cells before and after cryopreservation. (B) HBCs were cryopreserved by
using six different cryopreservation media. We counted the number of viable cells before and after cryopreservation. (C) Frozen HBCs
were seeded at various cell densities. We used FACS analysis to determine the percentage of AFP-positive cells. (D) The procedure
for freezing human iPS cell (1383D6)-derived HBCs is shown. Program Deep Freezer (PDF300) and cell cryopreservation solution
(Bambanker) were used. (E) Viable cells were counted before and after cryopreservation. (F) Nonfrozen HBCs and frozen HBCs were
differentiated into HLCs. The gene expression levels of hepatocyte markers (ALB, AAT, CYP3A4, and CYP2C9) were examined by
real-time RT-PCR. The gene expression level in nonfrozen HBC-derived HLCs was taken as 1.0. All data are represented as
means6SEM (n 5 3). Abbreviations: AAT, alpha-1 antitrypsin; CHRM, cryopreserved hepatocyte recovery medium; FACS,
fluorescence-activated cell sorting; RT-PCR, reverse-transcription polymerase chain reaction.
                                                                                                                                      
TAKAYAMA, AKITA, ET AL. HEPATOLOGY COMMUNICATIONS, December 2017
1064
                                                                                                                                      
FIG. 3. Safety assessment of human iPS cell-derived HLCs. (A) To perform the teratoma assay, undifferentiated human iPS cells
(13 105 cells/NOG mouse), human iPS cell (1383D6)-derived purified HBCs (13 105 or 13 107 cells/NOG mouse), and human
iPS cell-derived HLCs (13 105 or 13 107 cells/NOG mouse) were subcutaneously transplanted. At 4 or 16 weeks after transplanta-
tion, we determined the presence or absence of teratomas. Human iPS cells (Ff-l01s01) were used in the teratoma assay. (B) The
genomic sequence of human iPS cell (1383D6)-derived HBCs and HLCs was examined by targeted sequencing with a comprehensive
cancer panel. The genomic sequences of 596 cancer-related genes of human iPS cell-derived HBCs, purified HBCs, and HLCs were
compared with that of undifferentiated human iPS cells. To identify likely single-nucleotide substitutions that were newly generated in
differentiated cells, three independent somatic variant callers (LoFreq, MuTech, and VarScan2) were collectively used to reduce the
number of false-positive identifications.(16,17) (C,D) RNA sequencing was performed in undifferentiated human iPS cells, human iPS
cell-derived HBCs, purified HBCs, and HLCs. The messenger RNA expression profiles of (C) pluripotent markers and (D) hepato-
cyte markers are shown.
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(NOG mice) that were intraperitoneally inoculated
with 3mL/kg CCl4 1 day before transplantation (Fig.
4A). The survival rate of the mice after the iPS-HLC
transplantation (HLC-mice) was increased compared
with that of the mice after the sham operation (sham-
mice) (Fig. 4B). We examined therapeutic mecha-
nisms in the transplantation of human iPS-HLCs into
the acute liver injury model. Because we have found
that human iPS-HLCs secrete HGF,(4) the gene
expression levels of HGF in undifferentiated human
iPS cells, human iPS-HLCs, and PHHs were mea-
sured (Fig. 4C). The HGF expression levels in human
iPS-HLCs were significantly higher than those in
PHHs. To examine whether the therapeutic effects of
iPS-HLCs mediate HGF, HGF-knockdown human
iPS-HLCs were transplanted into acute liver injury
mice (Fig. 4D). The survival rate in the mice trans-
planted with human HGF small-interfering RNA
(si-HGF)-transfected human iPS-HLCs was signifi-
cantly decreased compared with the mice transplanted
with small-interfering control-transfected human
iPS-HLCs. These results suggest that the therapeutic
effects of human iPS-HLCs were mainly explained
by HGF secretion.
TRANSPLANTATION
OF HLA-homo iPS CELL-DERIVED
HLCs RESCUED MICE FROM
CHRONIC LIVER INJURIES
As chronic liver injury model mice, we used immu-
nodeficient mice (nude mice) that were intraperitone-
ally inoculated with 0.6 mL/kg CCl4 for 8 weeks
(twice weekly) before transplantation (Supporting Fig.
S9A). The gene expression levels of liver fibrosis
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FIG. 4. Transplantation of human iPS cell-derived HLCs rescued mice from acute liver injuries. (A) Human iPS cell (Ff-l01s01)-
derived HLCs were intrasplenically transplanted into mice that had been intraperitoneally inoculated with 3 mL/kg CCl4 1 day before
transplantation. (B) The survival rates of the mice after HLC transplantation (HLC-mice, square; n5 11) and sham operation (sham-
mice, circle; n5 12) were examined. (C) The gene expression levels of HGF in undifferentiated human iPS cells (iPS), human iPS
cell-derived HLCs (HLC), and PHHs were measured by real-time RT-PCR. On the y axis, the gene expression level in PHHs was
taken as 1.0. Data are represented as means 6SEM (n53). **, P<0.01. (D) The HLCs, which were transfected with si-control or si-
HGF, were transplanted into the mice that had been intraperitoneally inoculated with 3mL/kg CCl4 1 day before transplantation.
The survival rate of the mice after transplantation with si-control-transfected HLCs (si-control-transfected HLC-mice, squares;
n5 11), si-HGF-transfected HLCs (si-HGF-transfected HLC-mice, triangles; n5 12), or sham operation (sham-mice, circles;
n5 10) was examined; si-control versus si-HGF, P5 0.0496; si-control versus sham-mice, P5 0.0092; si-HGF versus sham-mice,
P5 0.1181. Abbreviations: RT-PC, reverse-transcription polymerase chain reaction; si, small-interfering RNA.
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markers (alpha-S-adenosyl methionine [aSAM],
desmin, neurotrophin receptor p75 [p75NTR], collagen
type 1 alpha 1 [COL1A1], matrix metalloproteinase 2
[MMP2], tissue inhibitor of metalloproteinase 1
[TIMP1], familial amyloid polyneuropathy [FAP]) in
the mice liver of the HLC-mice were significantly
lower than those of the sham-mice (Supporting Fig.
S9B). Consistently, Sirius Red staining showed that
the degree of progression of liver fibrosis was decreased
by iPS-HLC transplantation (Supporting Fig. S9C,
D). In intrasplenic hepatocyte transplantation, spleen
is sometimes removed after the transplantation to
avoid the effects of engrafted cells in the spleen. Thus,
we removed the spleen after hepatocyte transplanta-
tion. The therapeutic effects of human iPS-HLCs in
the mice transplanted with human iPS-HLCs fol-
lowed by spleen removal (spleen-removed mice) were
similar to those in the HLC-mice (Fig. S9B-D). This
result suggests that the therapeutic effects of HLCs do
not depend on the residual cells in the spleen. Consis-
tently, human ALB-positive cells were not observed in
the spleen, although a human ALB-positive cell cluster
was observed around the portal vein of the transplanted
mice (Supporting Fig. S9E). To evaluate the hepatic
functionality of engrafted cells, human ALB serum
levels in the transplanted mice were examined
(Supporting Fig. S9F). Human ALB serum levels in
the HLC-mice (approximately 350 ng/mL) were sig-
nificantly higher than that in the sham-mice. Taken
together, human iPS-HLCs have therapeutic potential
against chronic liver injuries.
Discussion
In this study, we showed that functional HLCs were
efficiently differentiated from HLA-homo iPS cells
without using feeder cells, Matrigel, and serum. The
risk of teratoma formation of human iPS-HLCs was
extremely low. In addition, genomic stability was con-
firmed during the hepatocyte differentiation procedure.
Finally, human iPS-HLCs were shown to have thera-
peutic potential against both acute and chronic liver
injuries.
It is known that undifferentiated human embryonic
stem (ES)/iPS cells can be maintained on a human
LN511- or LN521-coated dish but not on a human
LN111-coated dish.(13,18) We have reported that HBCs
differentiated from human pluripotent stem cells could
be maintained by using LN111.(14) It is also known that
human ES cells could be more efficiently differentiated
into HLCs on a mixture of LN521 and LN111 (ratio
of 1:3) than on Matrigel or pure LN521.(19) Therefore,
our finding that human iPS cells could be efficiently dif-
ferentiated to HBCs on a mixture of LN111-E8 and
LN511-E8 (ratio of 3:1) seems reasonable. In this
study, we used recombinant E8 fragments of laminins
(LN-E8), which are the minimum fragments conferring
integrin-binding activity, for hepatocyte differentiation.
Miyazaki et al.(12) reported that the yield of recombinant
proteins is much higher with LN-E8 than intact lami-
nin. Therefore, it might be possible to reduce the cost
and time involved in generating HBCs by using LN-E8
rather than intact laminins. In previous studies, Matrigel
was used to promote hepatocyte differentiation.(15,20-22)
We succeeded in generating functional HLCs by using
an LN111-E8-coated dish and overlaying thin type IV
collagen without using Matrigel. The main components
of Matrigel are LN111, type IV collagen, and elastin.
We consider that the conditions on Matrigel were
successfully mimicked by our LN111-E8-coated dish
overlaid with thin type IV collagen. Therefore, our
hepatocyte differentiation protocol should be a robust
method for generating human iPS-HLCs for therapeu-
tic applications. It is, however, worth noting the finding
of Baxter et al.(23) that human iPS-HLCs mimic fetal
hepatocytes better than they mimic adult hepatocytes.
Indeed, our human iPS-HLCs consistently expressed
fetal liver markers, such as AFP and CYP3A7 (data not
shown). Thus, further improvement of the hepatocyte
differentiation technology is needed.
In this study, we showed that the percentage of
residual undifferentiated cells could be reduced to
about 0.003% by performing HBC purification using
LN511-E8. Gropp et al.(9) showed that spiking of
13 104 undifferentiated human ES cells into 53 105
retinal pigment epithelium cells promoted teratoma
formation. However, spiking of lower numbers of
human ES cells (53 103, 13 103, and 13 102) did
not generate teratomas. Because the contamination of
up to 53 103 undifferentiated cells to human iPS-
HLCs can also be permissive, it is theoretically calcula-
ble that 1.63 108 human iPS-HLCs (the percentage
of undifferentiated cells is 0.00312%) can be trans-
planted without generating a teratoma. However, it is
known that teratoma formation capacity is strongly
dependent on the site of engraftment.(24) For this rea-
son, a teratoma formation assay should be performed
not only in the subcutaneous space but also in the liver.
The present study also confirmed that the genome
remains stable during the hepatocyte differentiation
process. Nonetheless, because mitochondrial DNA
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mutations are important causes of inherited disease,(25)
it will be necessary to examine the occurrence of mito-
chondrial DNA mutations in hepatocyte differentia-
tion. Finally, we also presented a method for the
cryopreservation of HBCs. This technique will provide
the technician with adequate time to perform a quality
check on the differentiated cells. Just as importantly, it
will afford an abundant supply and easy shipping of
human iPS-HLCs for medical applications.
In the present experiments we generated safe and
therapeutically effective human iPS-HLCs from an
HLA-homozygous donor. Our approach will contrib-
ute to the promotion of allogenic transplantation of
human iPS-HLCs. In a future study, we would like to
confirm the therapeutic potential of human iPS-HLCs
in an animal model larger than mice (such as pigs or
dogs) because the size of the livers would be closer to
that of humans.
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